{
    "2015-07-24": [
        "RT @BioStocks: Q2 Global Humira sales up 16.4% to $3.54B",
        "AbbVie shares slide 3.35% to $68.16 as the company reported weaker than expected Q2 revenue growth",
        "is an overleveraged time bomb with tP/E 61. Humira backfill &gt;&gt; 2q15 VPak miss $3B/yr target -49%, 2q15 Imbruvica miss $1B/yr target -6%",
        "RT @Bladeandbarrel: just a little? BLEW it, bigtime. Without contracts they have no uptake"
    ]
}